



Dear Dr. Last Name,

Your patient is curious about a new tool that can aid in the targeted therapy selection and treatment of rheumatoid arthritis (RA) and would like you to consider ordering the PrismRA® test.

PrismRA is a first-of-its-kind molecular signature test that gives providers objective insights to drive RA treatment decisions. The test analyzes each patients' unique molecular signature, predicting if they are well suited for TNF inhibitor (TNFi) therapies such as adalimumab, etanercept, infliximab, golimumab, and certolizumab pegol prior to starting or modifying therapy. PrismRA may be used before you prescribe a targeted therapy or before you modify treatment to better inform decision-making.

Incorporating PrismRA into clinical management of patients with RA can improve patient quality of life and save time by prescribing your patients a more effective therapy sooner.

This test is exclusively available from Scipher Medicine. To get started or learn more please give us a call at 855-724-7437 or email us at [provider\\_relations@scipher.com](mailto:provider_relations@scipher.com) and we will send you a starter kit including pre-paid shipping, test requisition forms, and instructions for specimen submission.

Respectfully,

Scipher Medicine Provider Relations Team  
855-724-7437  
[provider\\_relations@scipher.com](mailto:provider_relations@scipher.com)